EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study

Marie-Laure Laroche iD, Noémie Tarbouriech, Taha Jai, Marie-Blanche Valnet-Rabier iD, Virginie Nerich iD

British Journal of Clinical Pharmacology · 2025-02 · 91 (2) · 439-450

DOI: 10.1111/bcp.16266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 03.10.2024. Verfasst von Marie-Laure Laroche und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regional Pharmacovigilance Centre of Limoges, Department of Pharmacology-Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France. Hauptthemen laut MEDLINE: Hospitalization, Drug-Related Side Effects and Adverse Reactions, Cost of Illness. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Hospitalizations for adverse drug reactions (ADR‐HA) have increased over the last decade, but the impact of ADR‐HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR‐HA in France.

Methods

A partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR‐HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group‐based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3 months as from the first day of ADR‐HA). The robustness of the results was assessed using a one‐way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018.

Results

According to the 2018 tariffs ( vs . 2023), the mean total cost per patient with ADR‐HA was estimated at €5208 ± €3719 ( vs . €5974 ± €4232) ranging from €514 to €23 355 ( vs . €618 to €27 380). The total cost for 196 patients with ADR‐HA admitted to a sample of French public hospitals was estimated at €1 020 549 ( vs . €1 170 960). It could be estimated at €1.3 billion at the national level.

Conclusions

In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR‐HA weighs heavily on healthcare spending.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationDrug-Related Side Effects and Adverse ReactionsCost of IllnessHumansFranceRetrospective StudiesFemaleMalePharmacovigilanceMiddle AgedAgedAdultLength of StayAged, 80 and overYoung Adult

Stichwörter der Autor:innen

adverse drug reactionscost analysishospitalizationobservational studypharmacovigilance

Autor:innen und Institutionen

  • Regional Pharmacovigilance Centre of Limoges, Department of Pharmacology-Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France.
  • UR 24134 (VieSanté-Vieillissement, Fragilité, Prévention, e-Santé), IFR OMEGA HEALTH, Université de Limoges, Limoges, France.
  • Pôle Pharmacie, CHU Besançon, Besançon, France.
  • Centre Régional de Pharmacovigilance et d'information sur le médicament, CHU Besançon, Besançon, France.
  • CHU Besançon, INSERM, EFS-BFC, UMR 1098, Pôle Pharmacie, Université de Franche-Comté, Besançon, France.

ORCID-Profile: Marie-Laure Laroche, Marie-Blanche Valnet-Rabier, Virginie Nerich

Zitieren

APA

Laroche, M. L., Tarbouriech, N., Jai, T., Valnet-Rabier, M. B., & Nerich, V. (2025). Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study. British Journal of Clinical Pharmacology, 91(2), 439-450. https://doi.org/10.1111/bcp.16266

Vancouver

Laroche ML, Tarbouriech N, Jai T, Valnet-Rabier MB, Nerich V. Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study. British Journal of Clinical Pharmacology. 2025;91(2):439-450. doi:10.1111/bcp.16266

BibTeX
@article{Laroche2025,
  author = {Laroche, Marie-Laure and Tarbouriech, Noémie and Jai, Taha and Valnet-Rabier, Marie-Blanche and Nerich, Virginie},
  title = {Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {2},
  pages = {439--450},
  doi = {10.1111/bcp.16266}
}
Kostenlos starten →